Global Alkylating Agents Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2028

The global alkylating agents market is anticipated to grow at a significant CAGR 3% during the forecast period (2022-2028). Alkylating compounds are anti-neoplasmic therapeutic pharmaceuticals that are reactive in nature and include an alkyl group which binds to DNA, inhibiting malignant cell proliferation. It is regarded as a first-line treatment for a variety of cancers. Examples of alkylating agents include altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, and cyclophosphamide. Significant investment in research and development, high prevalence of chronic diseases, the rich promising pipeline of drugs, and high diagnostics rate are some of the major factors driving the growth of the global alkylating agents market.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

• In October 2021, Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the USFDA, has been launched by Dr. Reddys Laboratories, which is a lyophilized powder that comes in a package comprising a 100 mg Carmustine USP single-dose vial and a 3 mL sterile diluent vial.
• In July 2021, the USFDA approved Merck’s anti-PD-1 therapy, KEYTRUDA, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then as a single agent as adjuvant treatment after surgery, based on phase-3 KEYNOTE-522 trial.
• In April 2021, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan approved TREAKISYM ready-to-dilute (RTD) (bendamustine hydrochloride 120 mg/m2) liquid formulation as a treatment for relapsed or refractory diffuse large B-cell lymphoma in conjunction with rituximab (BR therapy).
• In March 2019, SunGen Pharma launched busulfan injection, the second product from its joint venture with Athenex Pharmaceuticals, Peterson Athenex.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Class
  • By Therapy Area
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Eagle Pharmaceuticals Inc., and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Alkylating Agents Market Report by Segment

By Drug Class

• Nitrogen Mustards
• Nitrosoureas
• Alkyl Sulfonates
• Triazines
• Ethylenimines
• Others

By Therapy Area

• Oncology
• Immunology
• Ophthalmology
• Dermatology
• Gastroenterology
• Urology
• Others